Research programme: small molecule therapeutics - Disarm Therapeutics

Drug Profile

Research programme: small molecule therapeutics - Disarm Therapeutics

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Washington University
  • Developer Disarm Therapeutics
  • Class Antiglaucomas; Neuroprotectants; Small molecules
  • Mechanism of Action SARM1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Glaucoma; Multiple sclerosis; Neurological disorders; Peripheral nervous system diseases

Most Recent Events

  • 19 Sep 2017 Disarm Therapeutics licensed IP covering SARM1 inhibitors from Washington University
  • 19 Sep 2017 Preclinical trials in Glaucoma in USA
  • 19 Sep 2017 Preclinical trials in Multiple sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top